Title : MIRROS: a randomized, placebo-controlled, Phase III trial of cytarabine ± idasanutlin in relapsed or refractory acute myeloid leukemia.

Pub. Date : 2020 May

PMID : 32167393






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Idasanutlin is a small-molecule inhibitor of MDM2, a negative regulator of tumor suppressor p53. RG7388 MDM2 proto-oncogene Homo sapiens
2 By preventing the p53-MDM2 interaction, idasanutlin allows for p53 activation, particularly in patients with TP53 wild-type (WT) status. RG7388 MDM2 proto-oncogene Homo sapiens